Lademirsen (sar339375) (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 218 | Alport syndrome | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02855268 (ClinicalTrials.gov) | November 2, 2019 | 28/7/2016 | Study of SAR339375 in Patients With Alport Syndrome | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of SAR339375 for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome | Alport's Syndrome | Drug: Lademirsen (SAR339375);Drug: Placebo | Genzyme, a Sanofi Company | NULL | Recruiting | 18 Years | 55 Years | All | 45 | Phase 2 | United States;Australia;China;France;Germany;Spain;United Kingdom |